Key clinical point: A reduction in the treatment cycle number of adjuvant chemotherapy with S-1 (Tegafur+ 5-chloro-2-4-dihydroxypyridine+oxonic acid) or capecitabine/oxaliplatin (CAPOX) in gastric cancer results in poorer survival outcomes.
Major finding: The 5-year overall survival rates in patients who received S-1 gradually increased from 48.4% to 55.4%, 64.1%, 71.1%, and 77.9% with an increase in cycle number from ≤5 to ≥8 cycles (P < .0001), with the same trend being observed with CAPOX (≤4 to ≥8 cycles: 43.5%, 45.3%, 47.1%, 55.3%, and 67.2%; P < .0001).
Study details: This retrospective study included 20,552 patients with gastric cancer who received 12-month S-1 (n = 13,614) or 6-month CAPOX (n = 6938) adjuvant chemotherapy.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Kim TH et al. Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: A retrospective nationwide cohort study. BMC Cancer. 2022;22(1):948 (Sep 3). Doi: 10.1186/s12885-022-10006-7